Search Results for: NKTR
At about 12:30 p.m. today, all three major US stock indexes are lower, with the DJIA down about 57 points at around12,920, the Nasdaq down about 31 points at 2,945, and the S&P 500 down nearly 8.5...
Published:
Football is often considered a game for warriors. You’ll usually find the toughest players on defense. Every time you step on the field, you’re expected to hit someone as hard as you can. You...
Published:
After opening lower this morning on weak data from Europe and Asia, the ISM non-manufacturing index for the US came in better than expected, but it was not enough to swing indexes toward gains....
Published:
Last Updated:
Student debt has ballooned in the United States in recent years. As of the end of 2023, Americans collectively owe some $1.73 trillion in student loans, more than double the outstanding balance at...
Published:
Nektar Therapeutics shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune and other chronic...
Published:
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
Published:
Last Updated:
Source: ThinkstockNektar Therapeutics (NASDAQ: NKTR) may have just burned a serious bridge for its future. The company is developing drugs for pain management and for cancer, and now its...
Published:
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results...
Published:
Last Updated:
Esperion Therapeutics and a few other biopharma stocks made massive runs on Monday morning.
Published:
Last Updated:
Bear Stearns’ (BSC) Jimmy Cayne will be stepping down as CEO but remaining as Chairman according to multiple reports. Credence Systems (CMOS) $0.05 EPS & $97.7M revenues vs. $0.05/$105M...
Published:
Nektar Therapeutics shares were crushed on Wednesday after the FDA did not recommend the company’s pain drug.
Published:
Hovnanian (HOV) House of pain for home builders. Down to $17.36 from 52-week high of $36.66. Pulte Homes (PHM) More of the same. Drops to $23.28 from 52-week high of $35.56. Lexmark (LXK) Jury finds...
Published:
Last Updated:
Telik (TELK) Biopharma has drug trial halted. Drops to $2.96 from 52-week high of $20.36. Cache (CACH) Women’s clothing store chain has poor same-store sales and lower guidance. Down to $14.14...
Published:
IMS Health (RX) Bad numbers and a downgrade. Falls to $21.20 from 52-week high of $33.12. The PMI Group (PMI) Housing and mortgage markets hurt quarter. Falls to $22.80 from 52-week high of $51.46....
Published:
Last Updated:
Stocks like these with a rising price-to-earnings (P/E) ratio can fetch strong returns.
Published: